.jpeg)
Is the imported drug Eltrombopag covered by national medical insurance?
The imported drug Eltrombopag has been covered by national medical insurance.
According to the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2022)" issued by the National Medical Security Administration, Eltrombopag has been included in the Category B Drug Catalog of Medical Insurance. This means that patients who are eligible for medical insurance reimbursement can enjoy part of the cost reimbursement when purchasing eltrombopag.
Eltrombopag's medical insurance reimbursement targets mainly patients with idiopathic thrombocytopenia who have failed previous treatments such as glucocorticoids and immunoglobulins. These patients are usually at higher risk of bleeding, and treatment with eltrombopag can significantly increase platelet counts and reduce the occurrence of bleeding events.
The specific reimbursement ratio varies depending on regions and medical insurance policies. Generally speaking, the reimbursement ratio for Class B drugs under medical insurance ranges from 50% to 70%. However, it should be noted that this ratio is not fixed and may change based on adjustments to local medical insurance policies.
Patients need to purchase Eltrombopag at the hospital and provide relevant diagnosis certificates and treatment records to the hospital to prove eligibility for reimbursement. The hospital will conduct reimbursement operations based on the patient's specific situation and local medical insurance policies.
To sum up, the imported drug Eltrombopag has been covered by national medical insurance. Patients who meet the conditions for medical insurance reimbursement can enjoy part of the cost reimbursement when purchasing Eltrombopag, thus reducing their financial burden. However, the specific reimbursement ratio and process may vary depending on the region and medical insurance policy. It is recommended that patients consult local medical insurance policies and hospital reimbursement processes in detail before purchasing.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
